MTOR and metabolic dysfunction-associated steatotic liver disease: Ajugol inhibits mammalian targets of mTOR and induces nuclear translocation of TFEB, thereby promoting the TFEB-mediated autophagy-lysosomal pathway and lipo autophagy to ameliorate NAFLD.